{"entity":{"id":"nct06971523","kind":"trial","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","aka":[],"tldr":"A phase 1/2 trial of CTS3497 in non-Hodgkin lymphoma, run by CytosinLab Therapeutics Co., Ltd., now recruiting.","summary":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies is a phase 1/2 interventional study registered as NCT06971523 by CytosinLab Therapeutics Co., Ltd., with 224 participants planned, started 2024-12-25 and due to reach its primary completion in 2028-12-31. Interventions recorded: CTS3497.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06971523","url":"https://clinicaltrials.gov/study/NCT06971523"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06971523","phase":"1/2","setting":"A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS3497 in Patients With MTAP Deficient Advanced Solid Tumors and Lymphomas","sponsor":"CytosinLab Therapeutics Co., Ltd.","enrolled":224,"outcomes":[]},"route":"/trials/nct06971523/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}